Hannah McDonald
September 4, 2012
Development of an RNA Aptamer for gp100
to enhance immunogenicity in malignant melanoma cells.
Abstract
Melanoma, or skin
cancer, is the most common form of cancer in the United States, accounting for
nearly 50% of all cases [1]. Cutaneous
malignant melanoma (CMM), causes the majority of skin cancer deaths (9,000 out
of the 12,000 per year in the U.S.) [2] yet only represents five percent of all
skin cancers. Whereas the mortality rate
for skin cancer has been decreasing due to early detection and removal, there
is still a need for treatment, especially when the tumor has been discovered
after metastasis [3,4].
Cancerous melanoma
tissues over express the biomarker glycoprotein gp100, making it an effective
diagnostic marker, though gp100 is also expressed at low levels on the surface
of normal melanocytes [5]. On it’s own,
gp100 elicits a weak immune response; recognizable by tumor-infiltrating
lymphocytes suggesting the target is accessible to the immune system [5]. Current intravenously administered immune
chemotherapies and radiation specifically target GP100 however, have they
increased toxicity likely due to attack of healthy tissues [6].
Aptamers are
oligonucleotides enriched through iterative rounds of nucleic acid in vitro
selection from a starting library containing roughly 1013. The SELEX
(Systematic Evolution of Ligands by Exponential Enrichment) method is designed
to create greater specificity and binding affinity towards target (protein) for
each subsequent round by getting rid of the species that don’t bind and
amplifying those that do. [7]
An aptamer
specific to gp100 has two main benefits over traditional therapies. First, drug delivery is relatively easy
through subcutaneous methods against melanomas as opposed to intravenous
administration mentioned above. The drug
could be formulated in a rub on cream that penetrates the skin. Second, using an immune redirection technique
[8], the aptamer could direct an immune response specifically to cells
expressing targets over a certain threshold such as gp100 on melanoma compared
to healthy melanocytes [9]. It is hoped
that this kind of aptamer therapy could greatly decrease the mortality rate
associated with CMM skin cancer.
Specific Aim # 1 - To develop an aptamer through iterative rounds
of nucleic acid enrichment that will specifically and tightly bind to human
gp100. Working with Altermune
Technologies, gp100 has been expressed and purified by GenScript (lot. No.:
163193S01/P20011204) with a poly-HIS tag for bead based selection.
Specific Aim # 2 - Once enrichment is detected, the selection will
continue with gp100+ melanoma cells such as human gp100 transfected mouse
melanoma B16 cells [10] and assayed using flow cytometry (FCM) to determine binding
affinity (using a negative-gp100 B16 cell line as the control).
Specific Aim #3 - Next-generation sequencing will be utilized to
interrogate the selected pool for specific binding variants.
Fig. 1. This figure outlines the specific aims of the
project as well as the general outline of the overall procedure.
[1] "Skin
Cancer Facts." Skin Cancer Facts. American Cancer
Society,
23 Jan. 2012. Web. 04 Sept. 2012.
[2] Jemal, A., et al. “Cancer Statistics, 2010.” A Cancer
Journal for Clinicians.
60(5):277-300.
[3] Leiter, U. and Garbe, C.. (2008)
“Epidemiology of Melanoma and Nonmelanoma Skin Cancer---The Role of
Sunlight.” Advances in Experimental Medicine and Biology. 624:Ch. 8.
[4] Lens, M.B., Dawes, M. (2004) “Global
perspectives of contemporary epidemiological trends of cutaneous malignant
melanoma.” British Journal of
Dermatology. 150(2):179-185.
[5] Salgaller,
M., et al. (1996) “Immunization
against Epitopes in the Human Melanoma Antigen gp100 following Patient
Immunization with Synthetic Peptides.” Cancer Research. 56: 4749.
[6] Dudley, M. E., et al. (2005). “Adoptive
Cell Transfer Therapy Following Non- Myeloblative
but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory
Metastatic Melanoma.” Journal of Clinical Oncology. 23(10):2346-2357.
[7] Brody, E.N., Gold, L. (2000). “Aptamers as therapeutic and diagnostic
agents.”
Reviews
in Molecular Biotechnology. 74(1):5-13.
[8] Popkov, M.,
Gonzalez, B., Sinha, S. C. & Barbas, C. F.(2009) “Instant immunity through
chemically programmable vaccination and covalent self-assembly.” Proc Natl
Acad Sci USA. 106, 4378–4383.
[9] Carlson, C.
B., Mowery, P., Owen, R. M., Dykhuizen, E. C. & Kiessling, L. L. (2007) “Selective tumor cell targeting using
low-affinity, multivalent interactions.” ACS
Chem Biol. 2: 119–127.
[10] Chen, H. et al. (2012). “Shikonin enhances efficacy
of a gene-based cancer vaccine via induction of RANTES.” Journal of Biomedical Science. 19(1):42.
2 comments:
Dear Hannah,
Here are some suggestions:
1. please add a budget section. Include the following:
detailed information about how the protein was obtained ...if it was made my GenScript, then say that.
* molecular weight,
* catalog number, if available, although if it was a custom synthesis, then it might not havce one.
* cost per a round
* include this is part of a "collaboration" w/ A*******
2. put citation inside punctation
3. it's = should be its (it's = it is)
4. be consistant w/ the use of GP100 ...
5. please don't use contractions ..
6. relocate budget stuff in specific aim #1 to its own budget section at the end.
7. specific aim #1 could be develop an anti-gp100 aptamer, while specific aim #2 could be develop an aptamer therapeutic.
8. if citing a website as a last resort, then pleaes include the URL
9. consider revisiting the figure.
Looks good! Good luck on your selection!
Gwen
Post a Comment